

Alexander A Navarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10721024/publications.pdf>

Version: 2024-02-01

46
papers

3,411
citations

186265

28
h-index

223800

46
g-index

48
all docs

48
docs citations

48
times ranked

5096
citing authors

#	ARTICLE	IF	CITATIONS
1	Ror ^{3t+} innate lymphocytes and ^{3t} T cells initiate psoriasiform plaque formation in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 2252-2256.	8.2	456
2	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. <i>Nature Medicine</i> , 2005, 11, 138-145.	30.7	356
3	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. <i>Nature Communications</i> , 2018, 9, 25.	12.8	194
4	Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1794-1800.	1.9	175
5	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	2.9	165
6	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	6.2	153
7	Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. <i>Journal of Clinical Investigation</i> , 2006, 116, 2456-2463.	8.2	150
8	Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. <i>European Journal of Immunology</i> , 2005, 35, 738-745.	2.9	149
9	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1366-1369.	0.7	140
10	Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15535-15539.	7.1	129
11	Interrupting IL-6 receptor signaling improves atopic dermatitis but associates with bacterial superinfection. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1128-1130.	2.9	123
12	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1067-1070.e9.	2.9	115
13	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1904-1907.	0.7	107
14	Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7107-7112.	7.1	93
15	Allergic Contact Dermatitis. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 141-152.	1.9	92
16	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2964-2970.	0.7	89
17	Involvement of Toso in activation of monocytes, macrophages, and granulocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2593-2598.	7.1	67
18	Generalized pustular psoriasis – a model disease for specific targeted immunotherapy, systematic review. <i>Experimental Dermatology</i> , 2018, 27, 1067-1077.	2.9	56

#	ARTICLE	IF	CITATIONS
19	Epidermal IL-15R α acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. <i>Journal of Experimental Medicine</i> , 2013, 210, 2105-2117.	8.5	55
20	Clinical Course and Characteristics of Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 21-29.	6.7	52
21	Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. <i>Blood</i> , 2009, 113, 1045-1052.	1.4	48
22	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. <i>BMJ Open</i> , 2021, 11, e043666.	1.9	48
23	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	2.1	39
24	Neutrophilic dermatoses and autoinflammatory diseases with skin involvement – innate immune disorders. <i>Seminars in Immunopathology</i> , 2016, 38, 45-56.	6.1	36
25	Marie Antoinette Syndrome. <i>Archives of Dermatology</i> , 2009, 145, 656.	1.4	33
26	Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature. <i>Dermatology</i> , 2013, 226, 302-310.	2.1	33
27	Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1 β after Azathioprine Exposure: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 293-298.	2.1	32
28	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. <i>Dermatology</i> , 2016, 232, 640-647.	2.1	32
29	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>PLoS ONE</i> , 2019, 14, e0210436.	2.5	26
30	Clinical Disease Measures in Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 39-50.	6.7	25
31	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	4.1	18
32	Canities subita : A reappraisal of evidence based on 196 case reports published in the medical literature. <i>International Journal of Trichology</i> , 2013, 5, 63.	0.5	17
33	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. <i>Dermatology</i> , 2021, 237, 166-178.	2.1	17
34	Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab. <i>Case Reports in Dermatology</i> , 2017, 9, 140-144.	0.8	15
35	Mucocutaneous Ulcerations and Pancytopenia due to Methotrexate Overdose. <i>Case Reports in Dermatology</i> , 2017, 8, 287-293.	0.8	14
36	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). <i>Archives of Dermatological Research</i> , 2019, 311, 753-760.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study. <i>Acta Dermato-Venereologica</i> , 2019, 99, 871-877.	1.3	11
38	Why henry III of navarre's hair probably did not turn white overnight. <i>International Journal of Trichology</i> , 2010, 2, 2.	0.5	8
39	Ecthymatous skin eruption during therapy with cetuximab. <i>European Journal of Dermatology</i> , 2011, 21, 282-283.	0.6	7
40	Generalized Pustular Eruptions: Time to Adapt the Disease Taxonomy to the Genetic Architecture?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 580-581.	0.7	5
41	Detection of Small Changes in Psoriasis Intensity with PrecisePASI. <i>Dermatology</i> , 2015, 230, 314-317.	2.1	4
42	Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice. <i>Journal of Investigative Dermatology</i> , 2018, 138, 726-728.	0.7	4
43	Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology. <i>Journal of Immunology</i> , 2005, 175, 5524-5531.	0.8	2
44	Worsening of Lymphopenia during Apremilast Treatment. <i>Case Reports in Dermatology</i> , 2017, 8, 319-322.	0.8	2
45	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 810-811.	2.9	2
46	Auto-inflammation and the Skin. , 2018, , 301-318.		0